Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Department of Hematology, St. Paul's Hospital, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada.
Curr Oncol. 2020 Dec 31;28(1):252-259. doi: 10.3390/curroncol28010027.
Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.
挽救复发 B 细胞急性淋巴细胞白血病 (B-ALL) 患者的选择包括奥加米星（InO），这是一种重组的、人源化的抗 CD22 单克隆抗体，与细胞毒性抗生素加利昔单抗偶联。然而，InO 在 CD22 表达较弱的患者中的获益尚不清楚。我们报告了一例 B-ALL 患者，尽管流式细胞术检测到 CD22 表面表达较弱，但对 InO 有反应，获得了与文献报道一致的生存获益，并作为无需输血的门诊患者保持了良好的生活质量。我们的观察结果对管理适合接受 InO 治疗的 B-ALL 患者的临床医生具有广泛的意义。
